Transgene

Report Publication Announcement • Sep 1, 2016

Transgene Announces Participation at Upcoming Investor Events

Strasbourg, France, September 1 st, 2016, 6:00 pm CET – Transgene today announced that management will participate in the upcoming investor events outlined below:

Rodman & Renshaw 18th Global Investment Conference:

September 12 & 13, 2016 - New York, USA

• Mid Cap Event: October 5 & 6, 2016 Paris, France
• Actionaria: November 18 & 19, 2016 Paris, France
• Natixis Mid Cap Conference: November 22, 2016 Paris, France

Next financial communication:

Financial results for the first six months of 2016 and business update: September 5, 2016 after market close

Contacts

Transgene:

Media contacts:

Lucie Larguier Director Corporate Communications & IR +33 (0)3 88 27 91 04 investorrelations@transgene.fr

Citigate Dewe Rogerson David Dible / Marine Perrier + 44 (0)20 7638 9571 transgene@citigatedr.co.uk

About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at www.transgene.fr.

Follow us on Twitter: @TransgeneSA